RNA-triggered cell killing with CRISPR-Cas12a2

  • Nature. 2026 Jul;655(8121):230-239. doi: 10.1038/s41586-026-10466-y.
Paul Scholz  #  1 Jared Thompson  #  2 Kadin T Crosby  #  3 Torsten Fauth  4 Nathan M Krah  2  5 Grant Schlauderaff  2 Robin Back  4 Zachary A Berkheimer  2 Alivia Jolley  2 Dirk Sombroek  4 Rebekka Medert  4 Christian Zurek  6 Oleg Dmytrenko  7 Emily Wilson  8 Friso T Schut  7 Jared Rutter  2  9 Xiaoyang Zhang  8 Michael Krohn  4 Ryan N Jackson  10 Chase L Beisel  11  12 Yang Liu  13
Affiliations
  • 1. Akribion Therapeutics GmbH, Zwingenberg, Germany. [email protected].
  • 2. Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • 3. Department of Chemistry and Biochemistry, Utah State University, Logan, UT, USA.
  • 4. Akribion Therapeutics GmbH, Zwingenberg, Germany.
  • 5. Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
  • 6. BRAIN Biotech AG, Zwingenberg, Germany.
  • 7. Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), Würzburg, Germany.
  • 8. Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • 9. Howard Hughes Medical Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • 10. Department of Chemistry and Biochemistry, Utah State University, Logan, UT, USA. [email protected].
  • 11. Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), Würzburg, Germany. [email protected].
  • 12. Medical Faculty, University of Würzburg, Würzburg, Germany. [email protected].
  • 13. Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, USA. [email protected].
  • # Contributed equally.
Abstract

Selectively eradicating target cells on the basis of their genetic or transcriptional identity remains important in basic research, medicine, biotechnology and agriculture1-3. For applications involving bacteria, CRISPR nucleases offer promising options due to their ability to enact RNA-guided counterselection4-7; however, using these same nucleases for counterselection in eukaryotes has proven much more restrictive8-14. Here we show that Cas12a2, a recently discovered type V CRISPR nuclease, exhibits RNA-triggered DNA shredding15,16, and enables programmable and sequence-specific elimination of yeast and human cells expressing a target transcript. Triggering Cas12a2 elicits rampant double-stranded DNA breaks in trans, leading to cell death. Cell killing can be activated by a wide range of target transcripts, with no observed off-target activation. Leveraging this approach, we selectively eliminate cells that harbour human papillomavirus, cells that failed to undergo gene editing, or cells that encode a prevalent oncogenic point mutation in KRAS. These findings expand the CRISPR toolbox to allow the selective elimination of eukaryotic cells on the basis of their transcriptional profile.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • 99.70%, KRAS G12C Inhibitor
    target: Ras
    Research Areas: Cancer